Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 18/20 | 0.78 |
| ▸ | PRKAB1 | Q9Y478 | 18/20 | 0.78 |
| ▸ | PRKAA2 | P54646 | 16/20 | 0.78 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.78 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.78 |
| ▸ | TFDP2 | Q14188 | 1/20 | 0.78 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.78 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12266853 | 0.90 | PRKAG1 (0.74) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL12563335 | 0.89 | PRKAG1 (0.79) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3036566 | 0.88 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL29376061 | 0.88 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL14823321 | 0.88 | PRKAG1 (0.73) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL30788331 | 0.88 | PRKAG1 (1.00) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL9909905 | 0.87 | PRKAG1 (0.60) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL12241833 | 0.87 | PRKAG1 (0.72) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL12266546 | 0.86 | PRKAG1 (0.70) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL12241664 | 0.86 | PRKAG1 (0.73) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422266-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9403790-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9278976-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150344487-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2015-12-03 | — | — | US | disclosed |
| US-9138426-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9073930-B2 | Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME (US) | 2015-07-07 | — | — | US | disclosed |
| US-9051329-B2 | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150126443-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2015-05-07 | — | — | US | disclosed |
| US-8980929-B2 | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150057220-A1 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS | MERCK CANADA INC. (CA) | 2015-02-26 | — | — | US | disclosed |
| US-20120149734-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2012-06-07 | — | — | US | disclosed |
| US-8143289-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC. (CA) | 2011-12-08 | — | — | US | disclosed |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. | 2011-10-27 | — | — | US | disclosed |
| US-20110183958-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. | 2011-07-28 | — | — | US | disclosed |
| US-20110166152-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-07-07 | — | — | US | disclosed |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2011-06-23 | — | — | US | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149734-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | PRKAG1 3757/4885PRKAB1 3898/4885PRKAA2 3288/4885 |
| US-20110166152-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, CPT1A | PRKAG1 1373/4885PRKAB1 1925/4885PRKAA2 422/4885 |
| US-20150126443-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | PRKAG1 3878/4885PRKAB1 3991/4885PRKAA2 3496/4885 |
| US-20110263533-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PRKAG1 2/4885PRKAB1 5/4885PRKAA2 12/4885 |
| US-20150344487-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | PRKAG1 3878/4885PRKAB1 3991/4885PRKAA2 3496/4885 |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PRKAG1 2/4885PRKAB1 5/4885PRKAA2 12/4885 |
| US-20150057220-A1 | FUSED AROMATIC PHOSPHONATE DERIVATIVES AS PRECURSORS TO PTP-1B INHIBITORS | PTPRS, PPM1B, PTPRF | PRKAG1 1290/4885PRKAB1 1193/4885PRKAA2 1556/4885 |
| US-20110183958-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FADS2 | PRKAG1 1099/4885PRKAB1 1508/4885PRKAA2 1414/4885 |
| US-20120010186-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, FASN | PRKAG1 844/4885PRKAB1 1326/4885PRKAA2 715/4885 |
| US-20110301143-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, COASY | PRKAG1 2995/4885PRKAB1 3160/4885PRKAA2 1873/4885 |
| US-20120142706-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, GCGR | PRKAG1 895/4885PRKAB1 1210/4885PRKAA2 1774/4885 |
| US-20110152295-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | PRKAG1 1265/4885PRKAB1 1676/4885PRKAA2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.